Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
VIR-7831
BIOLOGICAL
4 trials
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
, Eli Lilly and Company
, University of Liverpool
Conditions
COVID-19
Covid19
Phase 1
AGILE (Early Phase Platform Trial for COVID-19)
Recruiting
NCT04746183
University of Liverpool
Covid19
Start: 2020-07-03
End: 2026-07-31
Target: 600
Updated: 2026-01-14
Phase 2
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
Completed
NCT04634409
Eli Lilly and Company
COVID-19
Start: 2020-10-29
End: 2021-10-18
Updated: 2022-07-01
Phase 3
ACTIV-3: Therapeutics for Inpatients With COVID-19
Completed
NCT04501978
National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
Start: 2020-08-04
End: 2023-07-14
Updated: 2023-08-25
VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
Completed
NCT05780281
National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Start: 2020-12-16
End: 2022-10-04
Updated: 2023-12-27
Related Papers
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.
2026-03-18
Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial
Clinical Microbiology and Infection
2025-02-06
2 citations
P-1904. The Interaction of Serum Biomarkers and Lymphopenia on Pulmonary COVID-19 Illness Progression in Hospitalized Patients
Open Forum Infectious Diseases
2025-01-29
Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19.
2024-09-04
1 citations
Optimal dose and safety of intravenous favipiravir in hospitalized patients with SARS‐COV‐2: A phase I, open‐label, dose‐escalating, randomized controlled study
British Journal of Clinical Pharmacology
2024-09-01
Oral Favipiravir Exposure and Pharmacodynamic Effects in Adult Outpatients With Acute Influenza.
2024-08-01
6 citations
Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial.
2024-01-30
5 citations
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19
The Journal of Infectious Diseases
2023-11-09
4 citations
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
2022-11-26
32 citations
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
The Lancet Infectious Diseases
2022-10-19
75 citations
A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19
Frontiers in Medicine
2022-09-08
8 citations
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial.
2022-08-09
22 citations
Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)
Trials
2022-07-22
7 citations
Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial.
2022-07-08
96 citations
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
2022-06-07
173 citations
RAGE has potential pathogenetic and prognostic value in nonintubated hospitalized patients with COVID-19
JCI Insight
2022-03-17
27 citations
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Clinical Infectious Diseases
2022-03-09
18 citations
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
Science Translational Medicine
2022-01-25
208 citations
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
2021-12-23
173 citations
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.
2021-12-21
69 citations
6 more papers not shown